Get the Stockscreener App
3.12
4.88%
-0.16
Celularity Inc stock is traded at $3.12, with a volume of 71,503.
It is down -4.88% in the last 24 hours and up +52.20% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$3.28
Open:
$3.3
24h Volume:
71,503
Relative Volume:
0.31
Market Cap:
$74.72M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-1.9907
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
+5.41%
1M Performance:
+52.20%
6M Performance:
+52.20%
1Y Performance:
-0.95%
1-Day Range:
$3.10
$3.30
1-Week Range:
$3.04
$3.4999
52-Week Range:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
3.12 | 78.55M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
How does Celularity Inc. Equity Warrant compare to its industry peersStock Strategy Trend Scanner For Every Investor - jammulinksnews.com
Is it the right time to buy Celularity Inc. stockSwing Trade Entry Points For Fast Growth - jammulinksnews.com
Short Term Charts Align With Long Term Uptrend in Celularity Inc.Swing Setup With Technical Confirmation Explained - metal.it
Live Scanner Shows Breakout on Celularity Inc.Trade With Low Risk Exposure - beatles.ru
Celularity Inc. Equity Warrant Breaks Below Key Support LevelStep-by-Step Stock Investment Guide Gains Popularity - metal.it
What is the dividend policy of Celularity Inc. stockAdvanced Screener Guidance From AI Tools - jammulinksnews.com
Celularity Issues Promissory Note and Warrant - TipRanks
What catalysts could drive Celularity Inc. stock higher in 2025Expert Picks Signals To Watch Now - jammulinksnews.com
What are Celularity Inc. Equity Warrant company’s key revenue driversRetirement Planning Target Finder Backed By Experts - jammulinksnews.com
Is Celularity Inc. a growth stock or a value stockBest Dividend Guidance For Fast Growth - jammulinksnews.com
What is the risk reward ratio of investing in Celularity Inc. stockBeginner Investor Review Backed By Experts - jammulinksnews.com
Celularity Inc. Equity Warrant stock trend forecastFundamental + Technical Hybrid Stock Tips Shared - metal.it
Celularity Secures $2M Through Private Placement Deal - TipRanks
Celularity (CELU) raises $2M via private placement, issues warrants | PDS SEC FilingForm 6-K - Stock Titan
Relative strength of Celularity Inc. Equity Warrant in sector analysisLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Technical Charts Suggest Momentum Shift in Celularity Inc.Market Entry and Exit Point Tips From Traders - metal.it
What makes Celularity Inc. stock price move sharplyWeekly Stock Watch With Growth Focus Expanded - metal.it
Intrinsic Value of Celularity Inc. Stock: Is It Undervalued or OvervaluedTriple Digit Return Stock Predictions Released - metal.it
Options Data Show Bullish Bias in Celularity Inc.Risk Adjusted Technical Entry Plan Gains Followers - metal.it
Why Celularity Inc. Equity Warrant stock attracts strong analyst attentionAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Celularity Inc. Equity Warrant At Decision Level — Rebound or ResistanceChart Breakout Buy Signal Detection Confirmed - metal.it
What are the latest earnings results for Celularity Inc.Outstanding yields - jammulinksnews.com
Celularity Inc. Ranks High in Smart Money TrackerSmart Investment Tips Gaining Popularity Among Analysts - metal.it
What institutional investors are buying Celularity Inc. stockEarnings Report Outlook For 2025 - jammulinksnews.com
Should I hold or sell Celularity Inc. Equity Warrant stock in 2025Value Investing Report For 2025 - jammulinksnews.com
Celularity Inc. Equity Warrant Matches Institutional Buying FilterRisk Controlled Short Term Trade Plans Published - metal.it
When is Celularity Inc. stock expected to show significant growthFind market-beating stocks for your portfolio - jammulinksnews.com
Smart tools for monitoring Celularity Inc.’s price actionIntraday Strategy with Real Time Monitoring - Newser
When is Celularity Inc. Equity Warrant stock expected to show significant growthIdentify safe investments with exceptional yields - jammulinksnews.com
What is Celularity Inc. company’s growth strategyRecord-breaking capital gains - jammulinksnews.com
How strong is Celularity Inc. company’s balance sheetStock Market Report For Consistent Profits - jammulinksnews.com
What are analysts’ price targets for Celularity Inc. Equity Warrant in the next 12 monthsFree Stock Market Return Analysis - jammulinksnews.com
Is Celularity Inc. Equity Warrant stock overvalued or undervaluedInvest confidently with daily market forecasts - jammulinksnews.com
What institutional investors are buying Celularity Inc. Equity Warrant stockGrow your portfolio with growth-oriented stocks - jammulinksnews.com
What are the latest earnings results for Celularity Inc. Equity WarrantHigh-yield growth strategies - jammulinksnews.com
What are Celularity Inc. company’s key revenue driversMaximize gains with data-driven trading alerts - jammulinksnews.com
Key External Factors That Drive Celularity Inc. Stock Price MovementsMarket Beating Strategy - metal.it
Published on: 2025-07-27 22:22:50 - jammulinksnews.com
Celularity Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Stock Selection with 300% Return - Newser
What analysts say about Celularity Inc. stockExponential wealth increase - PrintWeekIndia
What analysts say about Celularity Inc. Equity Warrant stockFree Investment Community - PrintWeekIndia
Is Celularity Inc. stock overhyped or has real potentialFree Investment Community - jammulinksnews.com
What drives Celularity Inc. stock priceMarket-beating performance - PrintWeekIndia
Is Celularity Inc. Equity Warrant a good long term investmentSkyrocketing investment returns - PrintWeekIndia
Celularity Inc. Stock Analysis and ForecastMassive profits - PrintWeekIndia
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hariri Robert J | Chief Executive Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
3,281 |
0 |
21,482 |
| Haines John R | Senior Exec Vice President |
Apr 13 '25 |
Option Exercise |
0.00 |
1,641 |
0 |
29,698 |
| Beers David C | Chief Financial Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
1,025 |
0 |
18,561 |
| Brigido Stephen | Pres., Functional Regeneration |
Feb 17 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
11,641 |
| Beers David C | Chief Financial Officer |
Feb 17 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
21,932 |
| Haines John R | Senior Exec Vice President |
Feb 17 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
35,092 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):